Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 3
Key Clinical Considerations in HIV Treatment Decisions
The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.
BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question(s):
1. Three drug regimens have been the mainstay of successful HIV-1 treatment since 1996. Although we have seen improvement in the efficacy, adverse effects, and toxicities of contemporary three-drug regimens, even the newest therapies have potential adverse effects. Two-drug combinations are now part of the treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1 suppression. Gibas et al 2022
• Can you discuss two versus three drug regimens? Individualized care
